Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133


A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

Brezak MC, Quaranta M, Mondésert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B.

Cancer Res. 2004 May 1;64(9):3320-5.


Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.

Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, Kasprzyk PG, Prevost GP, Ducommun B.

Mol Cancer Ther. 2005 Sep;4(9):1378-87.


Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.

Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, Bahar I, Stephenson CR, Wipf P, Lazo JS.

Mol Pharmacol. 2004 Oct;66(4):824-33. Epub 2004 Jul 1.


Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.

Brun MP, Braud E, Angotti D, Mondésert O, Quaranta M, Montes M, Miteva M, Gresh N, Ducommun B, Garbay C.

Bioorg Med Chem. 2005 Aug 15;13(16):4871-9.


A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.

Aoyagi Y, Masuko N, Ohkubo S, Kitade M, Nagai K, Okazaki S, Wierzba K, Terada T, Sugimoto Y, Yamada Y.

Cancer Sci. 2005 Sep;96(9):614-9.


IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.

Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, Frongia C, Bigg D, Kasprzyk PG, Prevost GP, Ducommun B.

Int J Cancer. 2009 Mar 15;124(6):1449-56. doi: 10.1002/ijc.24080.


Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione.

Pu L, Amoscato AA, Bier ME, Lazo JS.

J Biol Chem. 2002 Dec 6;277(49):46877-85. Epub 2002 Sep 27. Erratum in: J Biol Chem. 2003 Apr 18;278(16):14586.


In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Kiyokawa H, Ray D.

Anticancer Agents Med Chem. 2008 Dec;8(8):832-6. Review.


CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø.

Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446.


Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.

Lavecchia A, Di Giovanni C, Novellino E.

Expert Opin Ther Pat. 2010 Mar;20(3):405-25. doi: 10.1517/13543771003623232. Review.


Antiproliferative effect of natural tetrasulfides in human breast cancer cells is mediated through the inhibition of the cell division cycle 25 phosphatases.

Viry E, Anwar A, Kirsch G, Jacob C, Diederich M, Bagrel D.

Int J Oncol. 2011 Apr;38(4):1103-11. doi: 10.3892/ijo.2011.913. Epub 2011 Jan 20.


Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.

Song Y, Lin X, Kang D, Li X, Zhan P, Liu X, Zhang Q.

Eur J Med Chem. 2014 Jul 23;82:293-307. doi: 10.1016/j.ejmech.2014.05.063. Epub 2014 May 27.


Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.

Capasso A, Cerchia C, Di Giovanni C, Granato G, Albano F, Romano S, De Vendittis E, Ruocco MR, Lavecchia A.

Oncotarget. 2015 Nov 24;6(37):40202-22. doi: 10.18632/oncotarget.5473.


Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.

Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, Mitchell DA, Furey W, Gussio R, Zaharevitz DW, Joo B, Wipf P.

Mol Pharmacol. 2002 Apr;61(4):720-8.


CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy.

Lavecchia A, Di Giovanni C, Novellino E.

Curr Med Chem. 2009;16(15):1831-49. Review.


Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited.

Potapova TA, Sivakumar S, Flynn JN, Li R, Gorbsky GJ.

Mol Biol Cell. 2011 Apr 15;22(8):1191-206. doi: 10.1091/mbc.E10-07-0599. Epub 2011 Feb 16.


Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells.

Brault L, Bagrel D.

Life Sci. 2008 Jan 30;82(5-6):315-23. doi: 10.1016/j.lfs.2007.12.001. Epub 2007 Dec 14.


Cell cycle regulation by the Cdc25 phosphatase family.

Nilsson I, Hoffmann I.

Prog Cell Cycle Res. 2000;4:107-14. Review.


Supplemental Content

Support Center